Effect of antihypertensive medications on the risk of open-angle glaucoma.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Glaucoma, Open-Angle*/drug therapy ; Glaucoma, Open-Angle*/epidemiology ; Hypertension*/drug therapy ; Hypertension*/epidemiology; Humans ; Antihypertensive Agents/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Angiotensin Receptor Antagonists/adverse effects ; Calcium Channel Blockers ; Diuretics/adverse effects

The purpose of this study was to identify the effect of antihypertensive medication on risks of open-angle glaucoma (OAG) among patients diagnosed with hypertension (HTN). A total of 5,195 patients, who were diagnosed with HTN between January 1, 2006 and December 31, 2015, and subsequently diagnosed with OAG, were selected for analysis. For each OAG patient, 5 non-glaucomatous, hypertensive controls were matched (n = 25,975) in hypertension diagnosis date, residential area, insurance type and economic status. Antihypertensive medications were stratified into 5 types: angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), β-blockers and diuretics. Relative risks were calculated. After adjusting for age, sex, body mass index, lifestyle, comorbidities, blood pressure (BP), follow-up duration, and use of other types of antihypertensive drugs, ARB and CCB were found to slightly increase OAG risks (RR 1.1087 (95% CI 1.0293-1.1942); 1.0694 (1.0077-1.1349), respectively). Combinations of ARB with diuretics (1.0893 (1.0349-1.1466)) and CCB (1.0548 (1.0122-1.0991)) also increased OAG risks. The risks for OAG were found to increase by antihypertensive medication use, but the effects appeared to be small. Further studies are necessary to identify the associations of increased BP, medication and therapeutic effect with OAG.
(© 2023. Springer Nature Limited.)

BMJ. 2012 Jan 12;344:d8190. (PMID: 22240117)
Arch Ophthalmol. 2007 Jun;125(6):805-12. (PMID: 17562992)
Am J Ophthalmol. 1988 Feb 15;105(2):155-9. (PMID: 3341432)
PLoS One. 2015 Jul 16;10(7):e0132048. (PMID: 26182236)
J Glaucoma. 2004 Aug;13(4):319-26. (PMID: 15226661)
Ophthalmology. 2018 Jul;125(7):984-993. (PMID: 29433851)
Am J Ophthalmol. 2006 Jul;142(1):60-67. (PMID: 16815251)
Circ Res. 2019 Mar 29;124(7):1061-1070. (PMID: 30920924)
Ophthalmology. 2019 Jul;126(7):967-979. (PMID: 30853468)
J Glaucoma. 2022 Jan 1;31(1):15-22. (PMID: 34731871)
Annu Rev Public Health. 2002;23:151-69. (PMID: 11910059)
Can J Ophthalmol. 2008 Jun;43(3):302-7. (PMID: 18493272)
Am J Ophthalmol. 2023 Aug;252:111-120. (PMID: 37030496)
Eye (Lond). 2020 Jan;34(1):12-28. (PMID: 31595027)
Circulation. 2008 Feb 12;117(6):743-53. (PMID: 18212285)
PLoS One. 2014 Sep 25;9(9):e108226. (PMID: 25254373)
Invest Ophthalmol Vis Sci. 1985 Mar;26(3):371-81. (PMID: 3972518)
Am J Ophthalmol. 2007 Aug;144(2):266-275. (PMID: 17543874)
J Glaucoma. 2007 Jun-Jul;16(4):406-18. (PMID: 17571004)
Ophthalmology. 2023 Sep;130(9):893-906. (PMID: 37150298)
Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):25. (PMID: 32931573)
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. (PMID: 17253471)
Prog Retin Eye Res. 2011 Jan;30(1):54-71. (PMID: 20933604)
Invest Ophthalmol Vis Sci. 2022 Mar 2;63(3):28. (PMID: 35353125)
Am J Ophthalmol. 2023 Oct 26;:. (PMID: 37898283)
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007185. (PMID: 20091622)
Ophthalmologica. 2012;228(1):36-41. (PMID: 22377835)
Lancet. 1999 Nov 20;354(9192):1803-10. (PMID: 10577657)
Ophthalmology. 2022 Feb;129(2):161-170. (PMID: 34474070)
BMJ Open. 2017 Sep 24;7(9):e016640. (PMID: 28947447)
N Engl J Med. 1999 Nov 4;341(19):1447-57. (PMID: 10547409)
Am J Ophthalmol. 2020 Oct;218:99-104. (PMID: 32360343)
J Glaucoma. 2013 Sep;22(7):526-31. (PMID: 22411020)
Ophthalmology. 2016 Mar;123(3):532-41. (PMID: 26746594)
Ophthalmology. 2007 Dec;114(12):2221-6. (PMID: 17568677)
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4548-4555. (PMID: 31675072)
JAMA. 2014 May 14;311(18):1901-11. (PMID: 24825645)
Curr Opin Ophthalmol. 1996 Apr;7(2):93-8. (PMID: 10163329)
Clin Exp Hypertens. 2016;38(4):409-14. (PMID: 27159660)
Ophthalmology. 2008 Jan;115(1):85-93. (PMID: 17629563)
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5800-4. (PMID: 19608537)
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001841. (PMID: 19588327)
Br J Ophthalmol. 2002 Jun;86(6):676-83. (PMID: 12034692)
Curr Eye Res. 1996 May;15(5):543-8. (PMID: 8670755)
Br J Ophthalmol. 2005 Aug;89(8):960-3. (PMID: 16024843)
Ophthalmology. 2021 Mar;128(3):393-400. (PMID: 32739337)
PLoS One. 2015 Oct 27;10(10):e0141137. (PMID: 26505191)
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3399-404. (PMID: 20164462)
Arch Ophthalmol. 2002 Jul;120(7):954-9. (PMID: 12096967)
J Curr Ophthalmol. 2016 Oct 20;29(1):7-16. (PMID: 28367520)
Clin Pharmacol Ther. 2019 Oct;106(4):874-883. (PMID: 31038730)
Arch Ophthalmol. 2002 Oct;120(10):1268-79. (PMID: 12365904)
Environ Res. 2023 Jun 15;227:115774. (PMID: 36966993)

0 (Antihypertensive Agents)
0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Angiotensin Receptor Antagonists)
0 (Calcium Channel Blockers)
0 (Diuretics)

Date Created: 20230927 Date Completed: 20230929 Latest Revision: 20231121

20240628

PMC10533509

10.1038/s41598-023-43420-3

37758842